샘플 요청 목록

 카트 문의
시장보고서
상품코드
1758052

세계의 기관지확장증 치료제 시장

Bronchiectasis Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 207 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 기관지확장증 치료제 시장은 2030년까지 11억 달러에 달할 전망

2024년에 6억 2,710만 달러로 추정되는 세계의 기관지확장증 치료제 시장은 2024-2030년에 CAGR 10.5%로 성장하며, 2030년에는 11억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 항생제는 CAGR 10.0%를 기록하며, 분석 기간 종료시에는 6억 6,870만 달러에 달할 것으로 예측됩니다. 거담약 부문의 성장률은 분석 기간 중 CAGR 11.8%로 추정됩니다.

미국 시장은 1억 7,090만 달러로 추정, 중국은 CAGR 14.1%로 성장 예측

미국의 기관지확장증 치료제 시장은 2024년에 1억 7,090만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR을 14.1%로 2030년까지 2억 3,300만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 7.6%와 9.2%로 예측됩니다. 유럽에서는 독일이 CAGR 약 8.2%로 성장할 것으로 예측됩니다.

세계의 기관지확장증 치료제 시장 - 주요 동향과 촉진요인 정리

기관지확장증이 호흡기 의학에서 중요한 초점으로 다시 떠오르는 이유는 무엇인가?

기관지확장증은 과거에는 희귀질환으로 여겨졌으나, 전 세계에서 유병률이 증가하고 만성적이고 쇠약해지기 쉬운 질환이라는 인식이 높아지면서 호흡기내과에서 다시 주목받고 있습니다. 기관지 확장증은 비가역적 기관지 확장, 만성 감염, 과도한 점액 생성을 특징으로 하는 기관지 확장증은 폐 기능과 삶의 질을 심각하게 손상시킵니다. 과거에는 낭포성 섬유증에 이차적으로 발생하는 드문 질환으로 여겨졌지만, 현재는 특히 노인과 호흡기 감염을 반복하는 사람들 사이에서 단독 비낭포성 섬유증(NCFBE)으로 진단되는 경우가 더 많습니다. 진단 능력의 향상, 특히 고해상도 CT 스캔의 보급은 전 세계에서 발견율 향상에 기여하고 있습니다. 이 질환은 면역 결핍과 감염 후 손상에서 자가면역질환과 만성 흡인에 이르기까지 복잡하고 불균일한 병인을 가지고 있으며, 맞춤 치료 전략이 필요합니다. 기관지확장증의 부담이 증가하고 있음에도 불구하고 현재 기관지확장증에 특화된 FDA 승인 약물은 없으며, 항생제, 항염증약, 기관지확장제, 점액용해제 등의 적응증 외 사용에 의존하는 대증요법에 의존하고 있는 실정입니다. 이러한 치료적 격차는 호흡기 치료제 시장에서 큰 미충족 수요를 유발하고 표적치료제에 초점을 맞춘 연구개발의 계기가 되고 있습니다. 임상의와 환자들 사이에서 기관지확장증에 대한 인식이 높아짐에 따라 기관지확장증은 무시당하는 질환에서 약물 개입의 전략적 타겟으로 전환되고 있으며, 감염을 조절하고 염증을 감소시키며 질환의 진행을 막기 위한 새로운 약제군 및 새로운 전달 시스템 개발이 촉진되고 있습니다.

기관지확장증 치료제의 파이프라인을 형성하는 치료 접근법은 무엇인가?

기관지 확장증의 현재 치료 전략은 주로 감염 제어, 염증 관리, 점액 제거 촉진, 악화 빈도 감소에 초점을 맞추었습니다. 토브라마이신이나 아즈트레오넘과 같은 흡입 항생제의 장기 사용은 특히 만성 녹농균 집락이 있는 환자에서 가장 널리 사용되는 옵션 중 하나입니다. 이러한 흡입 항생제는 박테리아의 양을 억제하고 폐 손상을 최소화하는 데 도움이 될 수 있습니다. 그러나 이러한 적응증 외 사용은 기관지확장증에 특별히 승인된 약물의 긴급한 필요성을 강조합니다. 아지트로마이신과 클라리스로마이신과 같은 경구용 마크로리드도 항생제 및 면역 조절제 역할을 모두 수행하며 항염증 작용을 통해 악화율을 감소시킵니다. 분무기를 통한 생리식염수나 만니톨은 일반적으로 처방되는 점액 용해제로서 기도의 통로를 개선하지만 근본적인 감염이나 염증에는 직접적으로 작용하지 않습니다. 최근 약물 개발 동향에서는 새로운 항염증약, 호중구 엘라스타제 억제제, CXCR2 길항제 등이 연구되고 있으며, 질병의 진행을 촉진하는 감염과 염증의 순환을 파괴하는 것을 목표로 하고 있습니다. 바이오 제약사들은 또한 중증 및 치료 저항성 환자에서 면역반응을 조절하는 IL-17 및 IL-8 경로 억제제와 같은 생물제제의 가능성을 연구하고 있습니다. 또한 약물과 기기의 병용요법 및 첨단 흡입 기술을 통해 하기도로의 약물전달 효율을 향상시키고 있습니다. 이는 기관지 확장 장애의 국소적 특성을 고려할 때 매우 중요합니다. 현재 기관지 확장증 환자를 위해 특별히 설계된 새로운 분자의 안전성과 효능을 평가하기 위해 여러 임상시험이 II상 및 III상 단계에 있습니다. 이러한 파이프라인의 혁신은 기관지확장증이 대증요법적 질환에서 약리학적으로 치료 가능한 질환으로 변화하고 있으며, 만성 호흡기 질환을 앓고 있는 수백만 명의 환자들에게 희망을 가져다 줄 수 있다는 점을 강조합니다.

인구통계학적 및 역학적 변화가 기관지확장증 치료제 시장 수요를 어떻게 견인하고 있는가?

기관지확장증 치료제 수요는 인구 고령화, 만성 호흡기 질환 증가, 진단 능력의 향상 등 인구통계학적, 역학적 추세에 의해 크게 형성되고 있습니다. 기관지확장증은 노년층에서 가장 많이 발생하며, 2050년까지 전 세계 60세 이상 인구는 두 배로 증가할 것으로 예상되며, 이에 따라 기관지확장증 부담도 증가할 것으로 예측됩니다. 고소득 국가에서는 영상 진단의 발전으로 인해 이전에 진단되지 않았던 사례가 발견되고 있으며, 특히 만성폐쇄성폐질환(COPD), 천식, 류마티스관절염 등의 질환을 동반한 환자에서 예상보다 높은 유병률이 밝혀지고 있습니다. 중저소득 국가에서는 홍역, 결핵, 폐렴과 같은 소아기 감염 질환이 미치료 또는 불충분한 관리로 인해 감염 후 기관지확장증이 흔하게 나타납니다. 또한 도시화, 대기오염, 흡연도 선진국, 개발도상국을 막론하고 큰 요인이 되고 있습니다. 또한 임상의의 인식 향상과 보고 시스템 개선으로 이 질환이 공중보건에 미치는 영향이 체계적으로 과소평가되고 있음이 밝혀졌습니다. 그 결과, 더 많은 환자들이 장기적인 관리가 필요한 만성 호흡기 증상으로 의료 시스템에 유입되고 있습니다. 제약사들은 기관지확장증의 만성적인 특성과 악화에 따른 높은 입원율을 고려할 때, 기관지확장증이 상업적으로 실행 가능한 치료 타겟임을 인식하고 있습니다. 경제적, 사회적 부담(의료비, 노동시간 손실, 삶의 질 저하 등)이 증가함에 따라 정부와 의료시스템은 기관지확장증 치료에 대한 투자를 우선순위로 삼고 있으며, 의약품 개발 및 접근성 확대에 대한 관심을 더욱 높이고 있습니다.

기관지확장증 치료제 세계 시장 성장을 가속하는 힘은 무엇인가?

기관지확장증 치료제 시장의 성장은 치료 패러다임의 변화, 헬스케어 우선순위의 변화, 호흡기 질환에 대한 R&D 투자 증가 등 여러 요인에 의해 주도되고 있습니다. 특히 승인된 질환 특이적 치료제가 없기 때문에 제약사들이 그 공백을 메우기 위해 임상시험 활동과 혁신 파이프라인이 활발히 진행되고 있습니다. 기관지확장증은 만성적이고 진행성이기 때문에 장기적인 약물 치료의 표적이 될 수 있으며, 환자들은 증상 조절과 악화를 예방하기 위해 지속적인 관리가 필요합니다. 또한 유전자 및 바이오마커를 기반으로 한 프로파일링이 가능해짐에 따라 환자 계층화가 촉진되어 정밀의료 접근 및 맞춤형 치료제 개발에 도움을 주고 있습니다. 진동식 메쉬 분무기, 건식 분말 흡입기 등 흡입 기술의 발전으로 폐에 영향을 받는 부위로의 약물전달이 개선되어 전신 부작용을 줄이면서 약물의 효능이 향상되고 있습니다. 또한 규제 당국은 희귀질환 및 소외된 질환에 대한 약물 개발을 장려하기 위해 보다 적극적으로 나서고 있으며, 적격 기관지확장증 치료제에 대해 패스트트랙 지정, 희귀질환 치료제 우대, 시장 독점권 등을 제공합니다. 상업적 측면에서 제약회사는 연구기관 및 생명공학 기업과의 전략적 파트너십을 통해 개발 기간을 단축하고 위험을 분담하고 있습니다. 신흥 시장 또한 헬스케어 인프라가 구축되고 호흡기 질환에 대한 인식이 확산됨에 따라 시장 침투의 새로운 기회를 제공합니다. 원격의료, 재택 분무기, 디지털 건강의 통합으로 질병 관리가 더욱 강화되고, 환자들의 치료 접근성이 향상되고, 치료 순응도가 향상되고 있습니다. 임상적 요구, 기술력, 세계 보건 정책에 기반한 이러한 복합적인 힘은 기관지확장증 치료제 시장을 환자 중심의 맞춤형 호흡기 치료의 새로운 시대로 이끌고 있습니다.

부문

제품(항생제, 거담약, 기타 제품), 유통 채널(온라인 유통 채널, 오프라인 유통 채널)

조사 대상 기업의 예(총 41건)

  • AbbVie Inc.
  • Akorn Operating Co. LLC
  • Amneal Pharmaceuticals Inc.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A.
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • GlaxoSmithKline plc(GSK)
  • Grifols S.A.
  • Hikma Pharmaceuticals plc
  • Insmed Incorporated
  • Lupin Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.

AI 통합

우리는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유 SLM을 조회하는 일반적인 규범을 따르는 대신에 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.08

Global Bronchiectasis Drugs Market to Reach US$1.1 Billion by 2030

The global market for Bronchiectasis Drugs estimated at US$627.1 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2024-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$668.7 Million by the end of the analysis period. Growth in the Expectorants segment is estimated at 11.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$170.9 Million While China is Forecast to Grow at 14.1% CAGR

The Bronchiectasis Drugs market in the U.S. is estimated at US$170.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$233.0 Million by the year 2030 trailing a CAGR of 14.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.6% and 9.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Bronchiectasis Drugs Market - Key Trends & Drivers Summarized

Why Is Bronchiectasis Re-Emerging as a Critical Focus in Respiratory Medicine?

Bronchiectasis, once considered an orphan condition, is now gaining renewed attention in respiratory medicine due to a rising global prevalence and increased recognition of its chronic and debilitating nature. Characterized by irreversible bronchial dilation, chronic infection, and excessive mucus production, bronchiectasis significantly impairs lung function and quality of life. Previously thought to be rare and mainly secondary to cystic fibrosis, the condition is now increasingly diagnosed as a standalone non-cystic fibrosis (NCFBE) entity, particularly among older adults and individuals with recurrent respiratory infections. Improved diagnostic capabilities, especially the widespread use of high-resolution CT scans, have contributed to higher detection rates worldwide. The condition’s complex and heterogeneous etiology-ranging from immunodeficiencies and post-infectious damage to autoimmune diseases and chronic aspiration-demands personalized treatment strategies. Despite its rising burden, there is currently no FDA-approved drug specifically indicated for bronchiectasis, making disease management largely symptomatic and reliant on off-label use of antibiotics, anti-inflammatories, bronchodilators, and mucolytics. This therapeutic gap has triggered a significant unmet need in the respiratory drug market and has become a catalyst for research and development efforts focused on targeted therapies. As awareness increases among clinicians and patients, bronchiectasis is transitioning from a neglected disorder to a strategic target for pharmaceutical intervention, prompting the development of new drug classes and novel delivery systems aimed at controlling infection, reducing inflammation, and halting disease progression.

What Therapeutic Approaches Are Gaining Ground in the Bronchiectasis Drug Pipeline?

Current treatment strategies for bronchiectasis primarily focus on controlling infections, managing inflammation, facilitating mucus clearance, and reducing exacerbation frequency. Long-term use of inhaled antibiotics, such as tobramycin and aztreonam, is one of the most widely used options, particularly in patients with chronic Pseudomonas aeruginosa colonization. These inhaled antibiotics help suppress bacterial loads and minimize lung damage over time. However, their off-label use highlights the urgent need for drugs specifically approved for bronchiectasis. Oral macrolides like azithromycin and clarithromycin also serve dual roles as both antibiotics and immunomodulatory agents, reducing exacerbation rates through their anti-inflammatory effects. Nebulized hypertonic saline and mannitol are commonly prescribed mucolytics that improve airway clearance but do not directly address the underlying infection or inflammation. Recent advancements in drug development are exploring novel anti-inflammatory agents, neutrophil elastase inhibitors, and CXCR2 antagonists aimed at disrupting the cycle of infection and inflammation that drives disease progression. Biopharmaceutical companies are also investigating the potential of biologics, such as IL-17 or IL-8 pathway inhibitors, to modulate the immune response in severe or treatment-refractory cases. Additionally, drug-device combination therapies and advanced inhalation technologies are improving drug delivery efficiency to the lower airways, which is crucial given the localized nature of bronchiectatic damage. Several clinical trials are currently in phase II and III stages, assessing the safety and efficacy of novel molecules designed specifically for bronchiectasis patients. These pipeline innovations underscore the ongoing transformation of bronchiectasis from a symptom-managed illness to a pharmacologically addressable disease, bringing hope to millions affected by this chronic respiratory disorder.

How Are Demographic and Epidemiological Shifts Driving Market Demand for Bronchiectasis Drugs?

The demand for bronchiectasis drugs is being significantly shaped by demographic and epidemiological trends, including aging populations, rising chronic respiratory illnesses, and improved diagnostic capabilities. The condition is most prevalent among older adults, and with the global population of individuals over 60 projected to double by 2050, the burden of bronchiectasis is expected to increase correspondingly. In high-income countries, advancements in diagnostic imaging have led to greater identification of previously undiagnosed cases, revealing a higher-than-anticipated prevalence, especially in patients with coexisting conditions like chronic obstructive pulmonary disease (COPD), asthma, and rheumatoid arthritis. In lower- and middle-income countries, post-infectious bronchiectasis remains common due to untreated or poorly managed childhood infections like measles, tuberculosis, or pneumonia. Urbanization, air pollution, and smoking are also major contributing factors across both developed and developing regions. Furthermore, increased clinician awareness and improved reporting systems have shed light on the systemic underestimation of this disease's impact on public health. As a result, more patients are entering the healthcare system with chronic respiratory symptoms demanding long-term management. Pharmaceutical companies are now recognizing bronchiectasis as a commercially viable therapeutic target, particularly given the chronic nature of the disease and the high rate of hospitalizations associated with exacerbations. The growing economic and societal burden-measured in terms of healthcare costs, workdays lost, and diminished quality of life-is further prompting governments and health systems to prioritize investment in bronchiectasis care, driving interest in drug development and access expansion.

What Forces Are Propelling Global Market Growth for Bronchiectasis Therapeutics?

The growth in the bronchiectasis drugs market is driven by several factors directly linked to shifting therapeutic paradigms, evolving healthcare priorities, and increased R&D investment in respiratory diseases. Foremost, the lack of approved, disease-specific treatments has created a high-value gap that pharmaceutical companies are racing to fill, leading to an uptick in clinical trial activity and innovation pipelines. The chronic and progressive nature of bronchiectasis makes it a lucrative target for long-term pharmacotherapy, with patients requiring continuous management to control symptoms and prevent exacerbations. Additionally, the growing availability of genetic and biomarker-based profiling is enhancing patient stratification, which supports precision medicine approaches and the development of tailored therapeutics. Advances in inhalation technologies-such as vibrating mesh nebulizers and dry powder inhalers-are improving drug delivery to affected lung regions, increasing efficacy while reducing systemic side effects. Moreover, regulatory agencies are becoming more proactive in encouraging drug development for rare and neglected conditions, offering fast-track designations, orphan drug incentives, and market exclusivity to qualifying bronchiectasis therapies. On the commercial front, pharmaceutical companies are leveraging strategic partnerships with research institutions and biotech firms to accelerate development timelines and share risk. Emerging markets are also presenting new opportunities for market penetration, as healthcare infrastructure improves and respiratory disease awareness spreads. Telehealth, home-based nebulization systems, and digital health integration are further enhancing disease management, allowing patients better access to treatments and increasing adherence. These combined forces-rooted in clinical need, technological capability, and global health policy-are driving the bronchiectasis drugs market into a new era of targeted, patient-focused respiratory care.

SCOPE OF STUDY:

The report analyzes the Bronchiectasis Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Antibiotics, Expectorants, Other Products); Distribution Channel (Online Distribution Channel, Offline Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Akorn Operating Co. LLC
  • Amneal Pharmaceuticals Inc.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A.
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • GlaxoSmithKline plc (GSK)
  • Grifols S.A.
  • Hikma Pharmaceuticals plc
  • Insmed Incorporated
  • Lupin Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Bronchiectasis Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Chronic Respiratory Conditions Throws the Spotlight on Bronchiectasis as an Under-Treated Disease
    • Growing Clinical Recognition and Diagnostic Rates Spur Demand for Targeted Bronchiectasis Therapies
    • Here's How Advances in High-Resolution Imaging Are Driving Earlier Diagnosis and Therapeutic Intervention
    • Expansion of the Elderly and Immunocompromised Population Strengthens the Business Case for Long-Term Drug Management
    • Increased Focus on Airway Inflammation and Mucociliary Dysfunction Supports Innovation in Anti-Inflammatory and Mucoactive Drugs
    • Here's the Story: How CF and Non-CF Bronchiectasis Subtypes Are Guiding Precision Drug Development Strategies
    • Rising Use of Real-World Evidence and Biomarker-Based Segmentation Enhances Drug Targeting and Patient Selection
    • Development of Combination Therapies with Bronchodilators and Corticosteroids Drives Portfolio Diversification
    • Global Expansion of Pulmonary Drug Delivery Platforms Supports Innovation in Inhalation-Based Treatment Options
    • Unmet Need for Disease-Modifying Therapies Presents Opportunities for Biologics and Novel Mechanism Agents
    • Increasing Focus on Patient Quality of Life and Symptom Burden Reinforces Market Demand for Long-Term Maintenance Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bronchiectasis Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Expectorants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Expectorants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • JAPAN
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • CHINA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • EUROPE
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • FRANCE
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • GERMANY
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • UNITED KINGDOM
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • SPAIN
    • TABLE 52: Spain Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Spain 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 54: Spain Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Spain 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Russia 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 58: Russia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Russia 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • AUSTRALIA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 70: Australia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Australia 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 72: Australia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Australia 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • INDIA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: India 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 76: India Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: India 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 78: South Korea Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: South Korea 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 80: South Korea Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: South Korea 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 82: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 84: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Asia-Pacific 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • LATIN AMERICA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 87: Latin America 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 88: Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Latin America 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 90: Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Latin America 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 92: Argentina Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Argentina 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 94: Argentina Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Argentina 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • BRAZIL
    • TABLE 96: Brazil Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Brazil 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 98: Brazil Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Brazil 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • MEXICO
    • TABLE 100: Mexico Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Mexico 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 102: Mexico Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Mexico 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 104: Rest of Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Latin America 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 106: Rest of Latin America Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Latin America 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • MIDDLE EAST
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 108: Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 109: Middle East 6-Year Perspective for Bronchiectasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 110: Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Middle East 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 112: Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Middle East 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • IRAN
    • TABLE 114: Iran Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Iran 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 116: Iran Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Iran 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • ISRAEL
    • TABLE 118: Israel Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Israel 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 120: Israel Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Israel 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 122: Saudi Arabia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Saudi Arabia 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 124: Saudi Arabia Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Saudi Arabia 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 126: UAE Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: UAE 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 128: UAE Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UAE 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 130: Rest of Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of Middle East 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 132: Rest of Middle East Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of Middle East 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030
  • AFRICA
    • Bronchiectasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 134: Africa Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Product - Antibiotics, Expectorants and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Africa 6-Year Perspective for Bronchiectasis Drugs by Product - Percentage Breakdown of Value Sales for Antibiotics, Expectorants and Other Products for the Years 2025 & 2030
    • TABLE 136: Africa Recent Past, Current & Future Analysis for Bronchiectasis Drugs by Distribution Channel - Online Distribution Channel and Offline Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Africa 6-Year Perspective for Bronchiectasis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel and Offline Distribution Channel for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제